StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$61.43+2.92 (+4.99%)

Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –

BioMarin Pharmaceutical revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

BioMarin Pharmaceutical's revenue for the twelve months ending Jun 30, 2026 was $3.41B, up 11.2% year over year. For fiscal 2025 it was $3.22B, up 12.9% from the year before. Over ten years it grew 13.7% a year on average. The highest annual figure on record is $3.22B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.22B+12.9%
FY2024Dec 31, 2024$2.85B+18.0%
FY2023Dec 31, 2023$2.42B+15.4%
FY2022Dec 31, 2022$2.10B+13.5%
FY2021Dec 31, 2021$1.85B-0.8%
FY2020Dec 31, 2020$1.86B+9.2%
FY2019Dec 31, 2019$1.70B+14.3%
FY2018Dec 31, 2018$1.49B+13.5%
FY2017Dec 31, 2017$1.31B+17.6%
FY2016Dec 31, 2016$1.12B+25.5%
FY2015Dec 31, 2015$889.90M+18.8%
FY2014Dec 31, 2014$749.28M+36.6%
FY2013Dec 31, 2013$548.49M+9.5%
FY2012Dec 31, 2012$500.72M+13.5%
FY2011Dec 31, 2011$441.36M+17.3%
FY2010Dec 31, 2010$376.27M+15.9%
FY2009Dec 31, 2009$324.66M+9.5%
FY2008Dec 31, 2008$296.49M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$989.71M+19.9%
Q1 FY2026Mar 31, 2026$766.21M+2.8%
Q4 FY2025Dec 31, 2025$874.57M+17.0%
Q3 FY2025Sep 30, 2025$776.13M+4.1%
Q2 FY2025Jun 30, 2025$825.41M+15.9%
Q1 FY2025Mar 31, 2025$745.15M+14.8%
Q4 FY2024Dec 31, 2024$747.31M+15.6%
Q3 FY2024Sep 30, 2024$745.74M+28.3%
Q2 FY2024Jun 30, 2024$712.03M+19.6%
Q1 FY2024Mar 31, 2024$648.83M+8.8%
Q4 FY2023Dec 31, 2023$646.21M+20.2%
Q3 FY2023Sep 30, 2023$581.33M+15.0%
Q2 FY2023Jun 30, 2023$595.28M+11.5%
Q1 FY2023Mar 31, 2023$596.42M+14.8%
Q4 FY2022Dec 31, 2022$537.54M+19.5%
Q3 FY2022Sep 30, 2022$505.34M+23.6%
Q2 FY2022Jun 30, 2022$533.80M+6.4%
Q1 FY2022Mar 31, 2022$519.36M+6.9%
Q4 FY2021Dec 31, 2021$449.81M-0.5%
Q3 FY2021Sep 30, 2021$408.74M-14.3%
Q2 FY2021Jun 30, 2021$501.69M+16.8%
Q1 FY2021Mar 31, 2021$486.03M-3.2%
Q4 FY2020Dec 31, 2020$452.12M-0.5%
Q3 FY2020Sep 30, 2020$476.78M+3.4%
Q2 FY2020Jun 30, 2020$429.49M+10.8%
Q1 FY2020Mar 31, 2020$502.07M+25.3%
Q4 FY2019Dec 31, 2019$454.44M+28.7%
Q3 FY2019Sep 30, 2019$461.10M+17.7%
Q2 FY2019Jun 30, 2019$387.76M+4.0%
Q1 FY2019Mar 31, 2019$400.75M+7.3%
Q4 FY2018Dec 31, 2018$353.21M-1.4%
Q3 FY2018Sep 30, 2018$391.71M+17.2%
Q2 FY2018Jun 30, 2018$372.85M+17.5%
Q1 FY2018Mar 31, 2018$373.45M+22.9%
Q4 FY2017Dec 31, 2017$358.31M+19.4%
Q3 FY2017Sep 30, 2017$334.15M+19.4%
Q2 FY2017Jun 30, 2017$317.45M–
Q1 FY2017Mar 31, 2017$303.75M–
Q4 FY2016Dec 31, 2016$300.09M–
Q3 FY2016Sep 30, 2016$279.90M–

More BioMarin Pharmaceutical figures

See a number that looks wrong?